FDA approval of Varipulse Platform to treat refractory paroxysmal atrial fibrillation – J&J Med Tech
Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, announced the FDA approval of the Varipulse Platform for the treatment of drug refractory paroxysmal Atrial Fibrillation… read more.
